Successful rescue therapy with darunabir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors.

Abstract

Darunabir, formerly TMC114, is a new protease inhibitor (PI) under clinical development designed to be active against HIV strains resistant to currently available PI. The virological and immunological response to ritonavir-boosted darunabir was assessed in four heavily antiretroviral-experienced patients who had failed enfuvirtide and two or more previous ritonavir-boosted PI regimens, including tipranavir in one instance. All four patients reached undetectable plasma HIV-RNA levels within 8 weeks of therapy and experienced significant CD4 cell count gains.

Cite this paper

@article{Poveda2006SuccessfulRT, title={Successful rescue therapy with darunabir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors.}, author={Eva Poveda and F. Garc{\'i}a Blanco and Pilar Garc{\'i}a-Gasc{\'o} and Antonio Alcolea and Ver{\'o}nica Briz and Vincent Soriano}, journal={AIDS}, year={2006}, volume={20 11}, pages={1558-60} }